Syon Capital LLC Invests $965,000 in Illumina, Inc. (NASDAQ:ILMN)

Syon Capital LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 6,933 shares of the life sciences company’s stock, valued at approximately $965,000.

Other institutional investors have also recently added to or reduced their stakes in the company. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Illumina in the third quarter valued at $29,558,000. abrdn plc raised its position in shares of Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after acquiring an additional 299,827 shares during the last quarter. International Assets Investment Management LLC raised its position in shares of Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after acquiring an additional 32,672 shares during the last quarter. Aquila Investment Management LLC lifted its stake in shares of Illumina by 150.0% in the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock worth $3,481,000 after acquiring an additional 15,000 shares during the period. Finally, Weil Company Inc. boosted its holdings in Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after acquiring an additional 8,539 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of recent analyst reports. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. Barclays upped their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $167.70.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is owned by corporate insiders.

Illumina Stock Performance

ILMN traded down $1.82 during trading on Thursday, hitting $121.05. 962,011 shares of the company traded hands, compared to its average volume of 1,729,585. Illumina, Inc. has a one year low of $89.00 and a one year high of $217.60. The stock’s fifty day moving average is $132.44 and its 200 day moving average is $127.54. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The firm has a market cap of $19.28 billion, a P/E ratio of -16.74 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.14 EPS. As a group, equities analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.